Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Samsung Electronics | Eli Lilly and Company | Lumentum Holdings | |
|---|---|---|---|
| Moat rating | narrow Samsung leads three of its four principal markets — Q1 2026 DRAM revenue share 38.5% ($37.32B, TrendForce, https://www.trendforce.com/presscenter/news/20260601-13070.html), Q1 2026 NAND share 31.6% ($13.51B, TrendForce, https://www.trendforce.com/presscenter/news/20260525-13058.html), and #1 in Q2 2026 smartphones at 24% (Counterpoint via Android Authority, https://www.androidauthority.com/counterpoint-research-q2-2026-smartphone-shipment-report-3686931/) — but the moat is narrow, not wide: memory economics are violently cyclical (industry DRAM revenue swung +81% QoQ on contract-price spikes per the same TrendForce release), SK hynix holds the highest HBM bit-shipment mix among the top three (same release), and foundry trails TSMC 6.5% vs ~72% share (TrendForce data via TelecomLead, https://telecomlead.com/semiconductor/global-foundry-market-hits-record-47-95-bn-in-q1-2026-as-ai-chip-demand-drives-growth-tsmc-expands-share-to-72-126247). | wide Eli Lilly's FY2025 10-K states "Intellectual property protection is critical" and that compound patents provide roughly 20-year market exclusivity ("patents in each relevant country last for a period of 20 years"), warning that loss of patent protection causes a "severe and rapid decline in revenues." Backed by an 83.0% gross margin (up from 81.3% in 2024) and a fast-growing, patent-protected incretin franchise (Mounjaro +99%, Zepbound +175% in 2025), the economic moat is wide and durable. Source: LLY FY2025 10-K. | narrow FY2025 10-K (filed 2025-08-19) grounds a narrow rating: on one side ~1,020 U.S. and ~1,100 foreign patents with expirations through 2045 plus vertically integrated wafer fabs (US, UK, Japan, Thailand) behind its laser chips and photonic ICs; on the other, Item 1A states optical communications products 'have increasingly become subject to commoditization' with 'predominantly Asia-based competitors' intensifying pricing pressure and a historical 'continued decline of average selling prices' expected to continue. |
| Moat type | cost scale The durable advantage is manufacturing scale and capital intensity: the top three DRAM suppliers take roughly $8.97 of every $10 of industry revenue (Samsung 38.5% + SK hynix 28.8% + Micron 22.4% in Q1 2026 per TrendForce, https://www.trendforce.com/presscenter/news/20260601-13070.html), a structure sustained by multi-billion-dollar fab economics that has admitted no new large entrant in decades; Samsung is the largest-revenue producer in both DRAM and NAND (TrendForce, https://www.trendforce.com/presscenter/news/20260525-13058.html). | intangibles ip Per the LLY FY2025 10-K, the pharma protection "anticipated to be of most relevance" is "patents claiming the active ingredient (the compound patent)," supplemented by regulatory data protection, FDA approvals, and brands — i.e., intangible assets. The 10-K notes that without such protection, products face intense generic and biosimilar price competition that erodes revenue quickly. | intangibles ip Per the FY2025 10-K, the moat rests on intangibles/IP and process know-how: patent portfolio (~1,020 U.S. / ~1,100 foreign, ~780 pending), InP laser and photonic-integrated-circuit technology (Oclaro, NeoPhotonics acquisitions), coherent DSP/ASIC lines (IPG telecom transmission acquisition), and its own wafer fabrication, assembly and test facilities — the company states it does not broadly license its IP absent adequate consideration or cross-licenses. |
| Leadership | co leader Revenue leader in DRAM (38.5%) and NAND (31.6%) in Q1 2026 (TrendForce) and #1 in Q2 2026 smartphone shipments (Counterpoint), but not the leader where AI value concentrates: SK hynix has the highest HBM bit-shipment mix among the top three DRAM suppliers (TrendForce, https://www.trendforce.com/presscenter/news/20260601-13070.html) and TSMC dominates foundry with ~72% share to Samsung's 6.5% (TrendForce via TelecomLead). | co leader Duopoly with Novo Nordisk: Novo's own FY2025 20-F names "Novo Nordisk and Eli Lilly [as] the most significant companies measured by market share" in the global diabetes and GLP-1 markets. Lilly is ascendant — the 20-F concedes Wegovy's years-long US anti-obesity prescription lead "was overtaken by a competing GLP-1 based product in the beginning of 2025" (Lilly's tirzepatide) — but Novo still cites Ozempic as "the leading product by sales," so co-leader is the honest band. Sources: Novo Nordisk FY2025 20-F; LLY FY2025 10-K. | co leader Mixed by layer: the FY2025 10-K self-describes Lumentum as 'a leading provider of optical and photonic products... recognized as an industry leader based on revenue and market share' (company's own characterization), while LightCounting's May 2026 optical vendor landscape places Lumentum near the bottom of its transceiver-only Top 10 — noting the list 'accounts for sales of optical transceivers only, excluding all other products, which explains lower rankings of Coherent and Lumentum' and that 'Neither CIG nor Lumentum plan to stay at the bottom of the list for much longer.' Co-leader in optical components/chips; follower in merchant transceiver modules behind Innolight and Eoptolink. |
| Pricing power | moderate Current pricing is extraordinary but cyclical, not structural: conventional DRAM contract prices rose roughly 93-98% QoQ in Q1 2026 (TrendForce, https://www.trendforce.com/presscenter/news/20260601-13070.html) — shortage-driven commodity pricing that reverses in downcycles. The set-side shows the limit: Samsung's own MX (smartphone) division posted a KRW 0.7 trillion operating loss in Q2 2026 on elevated component costs (Samsung Newsroom, https://news.samsung.com/global/samsung-electronics-announces-second-quarter-2026-results). | moderate Mixed. The LLY 10-K shows an 83.0% gross margin (up 1.7pp), evidence of strong list-price power on exclusive branded drugs; but it repeatedly notes 2025 revenue growth was "partially offset by lower realized prices" for both Mounjaro and Zepbound, alongside heavy PBM/formulary rebate pressure and default anti-obesity coverage restrictions (e.g., US self-insured employers "must generally opt in" for obesity-drug coverage). Net pricing power is therefore moderate, not strong. | moderate The May 5, 2026 Q3 FY2026 earnings release shows current pricing traction — CEO cites 'operational rigor, pricing discipline, and product mix' behind a 540 bps sequential non-GAAP gross-margin gain to 47.9% — but the FY2025 10-K states pricing pressures 'have led to a continued decline of average selling prices across our business and we expect that these historical trends will continue,' so power is cyclical/mix-driven rather than structural. |
| Summary | Samsung Electronics is the world's largest memory maker and a vertically integrated device company. In Q1 2026 it was #1 in DRAM (38.5% revenue share) and #1 in NAND (31.6%), and in Q2 2026 it retook #1 in global smartphones at 24% share. The AI-datacenter memory shortage produced record results: Q2 2026 company revenue of KRW 171.5 trillion and an all-time-high operating profit of KRW 89.5 trillion, with server memory reaching a record share of the sales mix and HBM4E samples shipped to major customers (Samsung Newsroom). The caveats that keep the moat narrow: the profit pool is a price cycle, not a structural annuity; SK hynix leads the highest-value HBM segment by bit-shipment mix; and Samsung Foundry, at 6.5% share versus TSMC's ~72%, remains a distant second in leading-edge logic despite expanding 2nm design wins. | Lilly's moat rests on patent-protected, FDA-approved branded medicines led by its tirzepatide incretin franchise: per the FY2025 10-K, Mounjaro ($22.97B) and Zepbound ($13.54B) together generated roughly 56% of 2025's $65.2B revenue (up 99% and 175% respectively), while compound patents confer ~20-year market exclusivity and support an 83.0% gross margin. Durable competition only emerges after patents and regulatory data protection lapse, at which point the 10-K warns generics and biosimilars drive a "severe and rapid decline in revenues." | Lumentum is an optical and photonics supplier whose FY2025 10-K describes two segments: Cloud & Networking ($1,410.8M of $1,645.0M FY2025 revenue) spanning datacom transceivers (Cloud Light), laser chips/EML transmitters, photonic ICs, co-packaged optics, optical circuit switches, and telecom transport (ROADMs, tunable and coherent components, pump lasers); and Industrial Tech ($234.2M) in fiber/ultrafast/diode lasers and 3D-sensing VCSELs. AI datacenter demand has inflected the business: the May 5, 2026 Q3 FY2026 release reports record revenue of $808.4M, up 90.1% YoY, with non-GAAP gross margin of 47.9% and the CEO crediting laser-chip strength, 'scale-across' components (pump lasers, narrow-linewidth laser assemblies), and pricing discipline, with co-packaged optics and optical circuit switches named as the next growth drivers. The moat is real but narrow: differentiation lives in photonic chip IP and vertical fab integration, while the transceiver-module layer commoditizes — LightCounting's May 2026 vendor landscape ranks Lumentum near the bottom of its transceiver-only Top 10 behind Innolight ($5.3B 2025 revenue) and Eoptolink, and Cignal AI (April 21, 2026) sizes 2025 datacom optical component revenue above $19B, up more than 70%, a market where scale rivals are growing as fast or faster. Customer concentration (top customers 16.0% and 15.4% of FY2025 revenue) and the 10-K's ASP-decline language cap the rating below wide. |
| Chain position | Upstream supplier of DRAM/HBM and NAND to the AI datacenter buildout (server memory at a record share of its Q2 2026 sales mix; HBM4E samples shipped to major customers) and a contract foundry, while simultaneously a downstream device maker (Galaxy) that consumes its own components (Samsung Newsroom, https://news.samsung.com/global/samsung-electronics-announces-second-quarter-2026-results). | Upstream branded-drug originator. Per the FY2025 10-K, US distribution flows through three wholesalers (McKesson, Cencora, Cardinal Health), each accounting for over 10% of consolidated revenue, into consolidated PBMs/payers whose formularies and rebate demands constrain net price; Lilly is also expanding a direct-to-patient channel, LillyDirect. | Upstream photonics supplier into AI/cloud datacenter and telecom infrastructure: sells transceivers, laser chips, CPO components and OCS to cloud operators, AI infrastructure providers and NEMs, and also supplies components to transceiver makers who compete with it ('Some of these competitors are also our customers' — FY2025 10-K). Concentrated demand: Customer A 16.0% and Customer B 15.4% of FY2025 net revenue; manufacturing concentrated in Thailand, China, UK, Slovenia, Japan and US with sole/limited-source component exposure. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.13 at weight 0.20 · swarm bullish Editorial prior, not backtested. | +0.30 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.13 at weight 0.20 · swarm bullish Editorial prior, not backtested. |